Estradiol valerate 1 mg - search results

United States - English - NLM (National Library of Medicine)

estradiol valerate and estradiol valerate/dienogest kit

sandoz inc - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 3 mg - estradiol valerate and estradiol valerate/dienogest is indicated for use by women to prevent pregnancy. the efficacy of estradiol valerate and estradiol valerate/dienogest in women with a body mass index (bmi) of > 30 kg/m2 has not been evaluated. estradiol valerate and estradiol valerate/dienogest is also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception [see clinical studies (14.2)]. do not prescribe estradiol valerate and estradiol valerate/dienogest to women who are known to have the following: there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. the administration of cocs to induce w

United States - English - NLM (National Library of Medicine)

estradiol valerate injection, solution

perrigo company - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 20 mg in 1 ml - estradiol valerate injection is indicated in the: 1. treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection should not be used in women with any of the following conditions: 1. undiagnosed abnormal genital bleeding. 2. known, suspected, or history of cancer of the breast. 3. known or suspected estrogen-dependent neoplasia. 4. active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5. active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial i

United States - English - NLM (National Library of Medicine)

natazia- estradiol valerate and estradiol valerate/dienogest kit

bayer healthcare pharmaceuticals inc. - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 3 mg - natazia® is indicated for use by women to prevent pregnancy. the efficacy of natazia in women with a body mass index (bmi) of > 30 kg/m2 has not been evaluated. natazia is also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception [see clinical studies (14.2)]. natazia is contraindicated in females who are known to have or develop the following conditions: there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. the administration of cocs to induce withdrawal bleeding should not be used as a test for pregnancy. cocs should not be used during pregnancy to treat threatened or habitual abortion. wo

United States - English - NLM (National Library of Medicine)

natazia- estradiol valerate and estradiol valerate/dienogest kit

physicians total care, inc. - estradiol valerate (unii: okg364o896) (estradiol valerate - unii:okg364o896) - estradiol valerate 3 mg - natazia™ is indicated for use by women to prevent pregnancy. the efficacy of natazia in women with a body mass index (bmi) of > 30 kg/m2 has not been evaluated. do not prescribe natazia to women who are known to have the following: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1 )] have cerebrovascular disease [see warnings and precautions (5.1 )] have coronary artery disease [see warnings and precautions (5.1 )] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1 )] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1 )] have uncontrolled hypertension [see warnings and precautions (5.